Uncategorized

07 Nov Pharma veterans guide next generation

Posted at 09:26h in Uncategorized

Pharmaceutical sector leaders and experts joined government and NGO representatives to share their collective wisdom with young researchers, entrepreneurs and industry professionals at The Bridge Program’s Residential Training Program last week. The Bridge Program was launched in 2017 to boost the commercial output of Australian pharmaceutical...

06 Nov Gloup to help 1 million Australians with difficulty swallowing medication

Posted at 12:26h in Uncategorized

Gloup™ makes swallowing tablets and capsules easier and is designed to have minimal impact on medication absorption. Mundipharma is proud to announce it has acquired the exclusive Australian and New Zealand distribution rights to the medication lubricant Gloup™, from Evomed Pty Limited (Evomed). Gloup™ is a medication...

02 Oct Mundipharma welcomes registration of Nyxoid® nasal spray for opioid overdose antidote1

Posted at 14:19h in Uncategorized

Mundipharma today welcomed the announcement by Federal Health Minister Greg Hunt MP that Nyxoid® (naloxone 1.8mg) nasal spray has been registered in Australia as an antidote to opioid overdose.1-4 At the moment, naloxone is only available in Australia for intramuscular or intravenous administration. Nyxoid® has been registered...

12 Sep Campaigns save lives – spread the word this Prostate Cancer Awareness Month

Posted at 16:58h in Uncategorized

Mundipharma has marked Prostate Cancer Awareness month by inviting leading urological surgeon, Associate Professor Paul Sved to share his insights from 20 years of clinical practice in the field. Employees outside the oncology business were eager to learn more about Mundipharma’s newest therapeutic area, after the...

17 Jul MUNDIPHARMA SUPPORTS PIONEERING PROSTATE CANCER RESEARCH

Posted at 13:06h in Uncategorized

The 2018 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has been awarded to Dr Kate Mahon, Medical Oncologist at Chris O’Brien Lifehouse, providing $60,000 to support her research into prostate cancer. This is the fifth annual Clinical Research Fellowship to be awarded in partnership with the Australian...

03 Jul MUNDIPHARMA BROADENS PAIN PORTFOLIO WITH INNOVATIVE PHYSICAL THERAPY DEVICES

Posted at 10:34h in Uncategorized

Mundipharma Pty Limited (Mundipharma) has added two innovative physical therapy devices to its pain management portfolio, acquiring the exclusive Australian and New Zealand rights to the PAINmate® and ActiPatch® brands from Evomed Pty Limited (Evomed). “Mundipharma is committed to the multimodal approach to pain management, which...

01 Jun Mundipharma partners with Kidsafe Australia for National Burns Awareness Month

Posted at 13:20h in Uncategorized

National Burns Awareness Month is a national campaign run by Kidsafe Australia with the support of mundicare® Burnaid® gel to raise awareness of the prevention and appropriate first aid measures for minor burns. The campaign is held in June each year as there is a significantly...

04 May Mundipharma launches mundicare® Cold Defence nasal spray

Posted at 00:01h in Uncategorized

Mundipharma has introduced a new early treatment to help families stay healthy and fight against the common cold. When taken at the first signs of a cold, mundicare® Cold Defence Nasal Spray is clinically proven to shorten the duration of a cold by up to 2...

27 Mar Subsidised Folotyn now available to all Australian’s in need

Posted at 10:10h in Uncategorized

Mundipharma has welcomed the announcement that the anti-cancer medicine Folotyn® injection (pralatrexate) will be subsidised for patients following its listing on the Pharmaceutical Benefit Scheme (PBS). Folotyn® is used to treat patients aged 18 years or older with peripheral T-cell lymphoma (PTCL) after previous treatments have...

19 Feb MUNDIPHARMA’S GROWTH PATH ON TRACK WITH ACQUISITION OF TOLMAR AUSTRALIA PTY LIMITED

Posted at 11:16h in Uncategorized

Mundipharma Pty Limited (Mundipharma) is continuing to grow and diversify with today’s acquisition of Tolmar Australia Pty Limited (Tolmar Australia), including exclusive distribution rights for the oncology medication Eligard® (leuprorelin acetate) in Australia and New Zealand. The deal follows several months of comprehensive due diligence...